First-trimester screening for Down syndrome using nuchal translucency measurement with free beta-hCG and PAPP-A between 10 and 13 weeks of pregnancy--the combined test

Prenat Diagn. 1999 Apr;19(4):360-3. doi: 10.1002/(sici)1097-0223(199904)19:4<360::aid-pd556>3.0.co;2-u.

Abstract

In a population of 1467 women attending the 'G. Gaslini' Institute for antenatal care, we evaluated first-trimester risk screening for Down syndrome using the 'combined test' based on ultrasound measurement of nuchal translucency (NT), maternal serum pregnancy-associated plasma protein A (PAPP-A) and free beta-hCG, and maternal age. No clinical action was taken on these results. The gestational age, determined by scan measurement of crown rump length, ranged from 10 weeks to 13 weeks 6 days. The median maternal age was 31 years 8 months. There were 13 Down syndrome pregnancies. The risk of having an affected pregnancy was estimated from a multivariate Gaussian distribution, using commercially available software. With a risk cut-off of 1 in 350, 11 affected pregnancies were detected (detection rate 85 per cent, 95 per cent confidence interval: 56-100 per cent) with a 3.3 per cent false-positive rate. The odds of being affected given a positive result were 1 in 30. Further data are needed to determine, with greater statistical reliability, the relative performance of the combined test with current second-trimester screening.

MeSH terms

  • Adult
  • Chorionic Gonadotropin, beta Subunit, Human / blood*
  • Down Syndrome / blood
  • Down Syndrome / diagnosis*
  • Down Syndrome / diagnostic imaging
  • Female
  • Gestational Age*
  • Humans
  • Maternal Age
  • Neck / diagnostic imaging*
  • Pregnancy
  • Pregnancy-Associated Plasma Protein-A / analysis*
  • Risk Factors
  • Sensitivity and Specificity
  • Ultrasonography, Prenatal*

Substances

  • Chorionic Gonadotropin, beta Subunit, Human
  • Pregnancy-Associated Plasma Protein-A